Mandate

Vinge advises Hansa Medical in connection with a directed share issue

November 15, 2018

The board of directors of Hansa Medical has resolved on a directed new issue of shares, whereby Hansa Medical will raise proceeds of approximately SEK 453 / USD 50 million, before issue costs.

The share issue is directed to a number of selected international and Swedish reputable investors and life sciences specialist investors, on the basis of an accelerated bookbuilding process conducted by Cowen, RBC Capital Markets and Skandinaviska Enskilda Banken.

Hansa Medical is a biopharmaceutical company developing novel immunomodulatory enzymes for organ transplantation and acute autoimmune diseases. The company’s lead product, imlifidase, is a proprietary antibody-degrading enzyme in late-stage clinical development for kidney transplant patients and has significant potential for further development in other solid organ transplantation and in acute autoimmune indications.

Vinge’s team has consisted of Dain Hård Nevonen, Erik Sjöman, Joakim Hagberg and Edin Agic. 
 

The Scope of Work According to AB 04

One of the most important parts of a construction agreement is the part where the scope of work is defined. There is a major difference between finding scope of work issues early in a construction project, instead of later during the execution phase.
May 04, 2021

A shift in EU merger control policy and practice could affect deal certainty and create opportunities for complainants

The European Commission is expanding its control of mergers and acquisitions within the existing legal framework, allowing national authorities to refer a transaction they do not have jurisdiction over for review in Brussels.
April 26, 2021

Vinge awarded Sweden Law Firm of the Year 2021 by Chambers & Partners

The award, Chambers Europe Award for Excellence – Sweden Law Firm of the Year 2021, is one of the foremost awards a Swedish law firm can receive. Vinge has previously received the award on four occasions.
April 23, 2021